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The endocrine cells confined in the islets of Langerhans are responsible for the
maintenance of blood glucose homeostasis. In particular, beta cells produce and
secrete insulin, an essential hormone regulating glucose uptake and metabolism. An
insufficient amount of beta cells or defects in the molecular mechanisms leading to
glucose-induced insulin secretion trigger the development of diabetes, a severe disease
with epidemic spreading throughout the world. A comprehensive appreciation of the
diverse adaptive procedures regulating beta cell mass and function is thus of paramount
importance for the understanding of diabetes pathogenesis and for the development of
effective therapeutic strategies. While significant findings were obtained by the use of islets
isolated from the pancreas, in vitro studies are inherently limited since they lack the many
factors influencing pancreatic islet cell function in vivo and do not allow for longitudinal
monitoring of islet cell plasticity in the living organism. In this respect a number of imaging
methodologies have been developed over the years for the study of islets in situ in the
pancreas, a challenging task due to the relatively small size of the islets and their location,
scattered throughout the organ. To increase imaging resolution and allow for longitudinal
studies in individual islets, another strategy is based on the transplantation of islets into
other sites that are more accessible for imaging. In this review we present the anterior
chamber of the eye as a transplantation and imaging site for the study of pancreatic islet
cell plasticity, and summarize the major research outcomes facilitated by this
technological platform.
Keywords: pancreatic islet imaging, islet transplantation, anterior chamber of the eye, confocal microscopy, islet
cell plasticity, beta cell, islet imaging, novel imaging methodsn.org April 2021 | Volume 12 | Article 6528531
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Diabetes mellitus is presently affecting large and growing segments
of the population, especially the elderly, and represents a major
socio-economic hurdle (1, 2). Constitutively high blood glucose is a
symptom of this disease and causes a number of severe pathologies
in multiple organs and cell types. Under normal conditions plasma
insulin levels typically increase when blood glucose levels rise, and
insulin serves as a signal for tissues throughout the body to take up
glucose, thereby maintaining blood glucose levels within a narrow,
physiologically optimal window. In the majority of cases, diabetes
results from a progressive dysfunction in the supply of insulin
secreted from the beta cells within the pancreatic islets, caused either
by an insufficient number of these endocrine cells or by their failure
to release adequate amounts of insulin in response to an increase in
blood glucose concentration. In this respect it is necessary to further
investigate the fine mechanisms linking glucose sensing to insulin
release and how pancreatic islets can adapt to different
circumstances to cope with varying insulin demands.
A major challenge in the longitudinal studies of islets is
related to the fact that these small structures only represent
about 1.5% of the total volume of the pancreas (3). Additionally,
the pancreas itself is located deep in the abdomen between other
organs and therefore not easily accessible for in vivo functional
imaging. Although in vitro studies based on islets isolated from
the pancreas brought significant advances to the understanding
of islet biology, these are unfortunately inherently limited since
they lack the many factors influencing pancreatic islet cell
function in vivo, e.g. the effects of hormones secreted from a
crosstalk with other organs such as liver, adipose tissue, brain,
and gut (4, 5). Therefore, studies under the complex in vivo
conditions present in the living organism are primordial for the
longitudinal appreciation of islet function in health and disease.
A number of different advanced imaging techniques have
been developed over the years for the study of pancreatic islets,
with a particular focus on their ability to estimate beta cell mass,
i.e. a volumetric measurement of insulin-positive cells (6). In
particular, magnetic resonance imaging (MRI), positron
emission tomography (PET), computer tomography (CT) and
bioluminescence imaging (BLI) are the main imaging modalities
used for in vivo noninvasive studies of islets in the pancreas.
However, while these techniques offer appropriate imaging
penetration for animal studies, they are still limited in terms of
sensitivity and resolution and often require additional labeling
for the detection of beta cells. Other techniques to image in situ
pancreatic islets at higher resolution include optical projection
tomography (OPT), light sheet fluorescence microscopy (LSFM),
optical coherence tomography (OCT) and confocal microscopy,
but require exteriorization or removal of the pancreas and
therefore are not suitable for longitudinal imaging at single
islet level. Alternatively, abdominal imaging windows have
been installed with the aim of imaging islets in situ without
delocalizing the pancreas (7, 8). While this solution allows for a
repetitive optical assessment of individual islets, the number of
imaging sessions is still limited and the procedure is technically
very challenging.Frontiers in Endocrinology | www.frontiersin.org 2Due to difficulties in imaging islets longitudinally in the intact
pancreas, another strategy is based on transplantation of islets
into other sites that are more accessible for imaging. One
important aspect in this case, in addition to the possibility to
image the islets at high resolution, is the proper engraftment and
survival of transplanted islets. Revascularization and
reinnervation are indeed primordial factors determining the
outcome of islet transplantation due to their critical role in the
maintenance of islet functionality and survival (9–11). In
particular, intra-islet vessels require a fast formation for tissue
oxygenation, and furthermore their endothelial cells have been
shown to be involved in local interactions with beta cells that are
of particular importance for islet function (12).
Multiple sites have been explored for islet transplantation (13).
In particular the kidney subcapsular space, the spleen and the
portal vein have been widely used for the in vivo evaluation of islet
mass and function, albeit with varying levels of engraftment
success (14, 15) and of accessibility for high resolution imaging.
Another approach is based on the transplantation of pancreatic
islets into the anterior chamber of the eye (ACE). Because of its
optical and structural properties, the eye is optimally suited as a
natural body-window for non-invasive and longitudinal imaging
of single islet grafts and their vascularization. Islets transplanted
into the ACE have been shown to be functional and various
aspects of beta cell function and survival can be readily imaged in
this environment. Furthermore, imaging islets at this site can be
performed at relatively high speed and at resolutions allowing for
single cell functional investigations, essential requirements for the
assessment of beta cell heterogeneity and dynamics of intra-islet
cellular communications (16). In the following we will review
findings obtained by the use of the ACE as a transplantation/
imaging site for longitudinal in vivo appreciation of pancreatic
islet cell mass and function.THE ACE AS A TRANSPLANTATION SITE
AND THE CORNEA AS A NATURAL BODY
WINDOW FOR IMAGING PANCREATIC
ISLET CELLS
The anterior chamber of the eye has been used as a
transplantation site for about 150 years (17) and was shown in
a number of studies to allow for the adequate engraftment of
tissues from various origins, such as heart, brain, muscle,
pituitary gland, liver, prostate, or tumors (18–23). The dense
vascular network in the iris is contributing to rapid
revascularization of the tissues (23, 24), providing essential
nutrients and oxygenation for graft survival. In particular,
pancreas tissue has been shown to benefit from proper survival
after transplantation into the ACE (24–27). First seen as a
convenient location for in vivo tissue culture and observation,
this transplantation site has since been combined with high
resolution microscopy for the assessment of islet morphology
and function at individual islet and single cell level (28, 29). In
addition to the benefits of this transplantation site for isletApril 2021 | Volume 12 | Article 652853
Ilegems and Berggren Imaging Islet Plasticity Through the Eyeengraftment and imaging, the surgical procedure is particularly
straightforward and is not causing pain nor affecting the vision of
the recipient animal (30).
After their introduction into the ACE through a small
perforation in the cornea, the islets attach to the iris, initiating
their engraftment. A few days after transplantation,
revascularization of the tissue starts by the appearance of large
blood vessels, followed progressively by smaller capillaries (31).
Approximately 4 weeks after transplantation islet grafts are
completely vascularized and present a similar vascular density
as compared to islets in the pancreas (28). Interestingly, it has
been shown that the newly-formed vascular network originates
from the combination of endothelial cells still residing within the
transplanted islet and of endothelial cells emanating from the iris
(32). It is important to note that, even when using islets or
pseudoislets completely devoid of endothelial cells for
transplantation, capillaries emanating from revascularization
comprise fenestrations (32, 33), similar to those from islets in
the pancreas and required for the optimal transit of compounds
between endocrine cells and blood flow. The eye also benefits
from a dense innervation, contributing to the supply of
sympathetic and parasympathetic fibers to the transplanted
tissue (18). Reinnervation of islets starts within a few days and
reaches a plateau 3 months after transplantation, with a pattern
dictated by the transplanted islet (34). Thus both the innervation,
of importance for the modulation of insulin release (35), and the
connection of the islet grafts to blood circulation are occurring in
the ACE, a prerequisite for any comprehensive investigation of
islet biology.
There are basically two transplantation strategies, each giving
different information on islet function (Figure 1). Firstly, the
transplantation of a small number of islets, so-called “reporter
islets”, will serve to indicate the function of islets in the pancreasFrontiers in Endocrinology | www.frontiersin.org 3without affecting overall blood glucose homeostasis. Secondly,
the transplantation of a large number of islets (“metabolic
transplantation”) into the ACE of mice rendered diabetic by
the destruction of their pancreatic beta cells will regulate overall
blood glucose homeostasis by secreting sufficient amounts of
insulin in response to high glycemic levels, thereby taking over
the role of islets in the pancreas. While the success of this latter
procedure depends on the number of transplanted islets (37), it is
interesting to note that only about 100 islets are required for
complete recovery of blood glucose handling. Both
transplantation strategies can be combined by the use of both
eyes for transplantation, increasing the possibilities for
scientific investigations.
A wide range of parameters related to islet function under
normal and pathological conditions can be investigated by the
use of the ACE as an in vivo transplantation/imaging platform
(see Table 1). To start with, information on the morphology of
the islet as well as its volume can be obtained by image
acquisition of light scattering from islet cells. Indeed, secretory
granules in beta cells are densely packed with crystallized insulin,
forming microscopic spherical mirrors that are major
contributors to the islet intrinsic scattering properties and
permit to obtain volumetric information at cellular resolution
without extrinsic labeling (39). Moreover, due to this biological
origin, the intensity of light scattering is thereby directly
indicative of insulin secretory capacity in islets. The recorded
signal will thus be diminished both in cases of hypersecretion
(36, 39) and of degranulation following autoimmune attack (53–
55), thereby giving valuable insights into the functional status of
transplanted islets.
Imaging strategies and probes for the investigation of cellular
function are being continuously developed, many of which can
be directly applied to the study of islet function in vivo afterA B
FIGURE 1 | Two transplantation strategies for in vivo study of pancreatic islet function and plasticity. (A) Various aspects of pancreatic islet function and morphology
have been shown to be mirrored in “reporter islets” in the eye (36). This illustrative example shows that changes occurring to the in situ pancreatic islets of an obese
mouse (right), for instance beta cell hyperplasia, are similarly occurring to the islets transplanted into the ACE. (B) Mice rendered hyperglycemic, e.g. by streptozotocin
(37) or diphteria toxin (38), can be recovered by “metabolic transplantation” of a large number of islets, taking over the function of damaged pancreatic islets.April 2021 | Volume 12 | Article 652853
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to insulin secretion, can now be readily imaged at various
temporal resolutions (33, 39–41, 46–48). Probably the most
studied signal in the beta cell signaling pathway is the change
in cytoplasmic free Ca2+ concentrations ([Ca2+]i), for its central
role in the secretion of insulin (60). This signal was first studied
in islets engrafted into the ACE after intraocular incubation with
a [Ca2+]i-sensitive fluorescent dye prior to in vivo activation with
glibenclamide (28). Transgenic mice expressing genetically
encoded fluorescent [Ca2+]i indicators were later used to
record beta cell responses to intravenous administration of
glucose (41, 46, 47) and of vasopressin, an agonist for the beta
cell expressed V1b receptor (a G protein-coupled receptor,
GPCR) (33). Whereas the response to the GPCR agonist was
immediate, glucose initiated a slightly slower increase in [Ca2+]i
that culminated about 50s after administration, followed by
smaller oscillating signals that gradually disappeared in parallel
to the subsequent decrease in blood glucose levels. These
experiments showcase how in vivo experiments take into
account the many factors (e.g. circulating glucose and
hormone levels) whose complexity cannot be faithfully
reproduced under in vitro conditions.
Although the ACE was previously thought to be an immune
privileged site (61), as aforementioned it has been shown that islets
could be subjected to autoimmune attack at this location (58).
Moreover, the infiltration of T lymphocytes into islet grafts is
supportive of the notion that the immune privilege is somehow
lost during the transplantation/engraftment procedure, and that
the ACE is well-suited for longitudinal in vivo studies of
autoimmunity and allograft rejection. This also implies that
rejection of islets originating from another genetic background/
species will occur in unmatched recipient mice, but this can be
circumvented by the use of immune-deficient mice. This is
particularly attractive for the study of human islets and thereby
for appreciating to which extent studies performed in rodents can
be translated to humans. For instance human islets indeed differ
from rodent islets in their endocrine cell content and architecture
(62, 63) as well as in their innervation pattern and density (64),
thereby displaying functional differences that can now be assessedFrontiers in Endocrinology | www.frontiersin.org 4in vivo using the ACE platform (65, 66). Furthermore, the
possibility to study human islets longitudinally represents an
important asset in that it allows to evaluate short- and long-
term effects of pharmacological treatment strategies for diabetes.
This has been done for evaluating long-term effects of the beta cell
targeting antidiabetic drug liraglutide (65). In this study mice were
rendered diabetic by administration of streptozotocin (STZ),
followed by a “metabolic transplantation” of human islets. Mice
treated systemically with liraglutide returned to normoglycemic
levels in a shorter period of time than their controls, indicating a
beneficial short-term effect. However, upon prolonged treatment
the transplanted islets became dysfunctional, unable to maintain
sufficient insulin release to sustain normal glucose levels. These
findings indicate that an excessive stimulation of beta cells with
liraglutide leads to beta cell exhaustion and failure, which may be
of immediate relevance for the outcome of long-term treatment of
type 2 diabetes patients with this kind of drugs.
It is therefore possible to study in detail the effect of a
pharmacological treatment on beta cell function and survival by
systemic administration using this methodological platform.
Interestingly, due to the specific location of the transplanted
islets it is also possible to proceed with topical drug delivery,
targeting more directly the engrafted tissue. In particular,
compounds can be administrated locally by the application of
eye drops (66) or by the slow release of compounds from co-
transplanted micro-containers (67), thereby circumventing
potential systemic adverse effects and reducing the overall
treatment dosage. Finally, in addition to the advantages of using
the ACE for islet transplantation and assessment, this accessible
site can be used for analyzing compounds accumulating in the islet
micro-environment (50–52). Microliter-size aqueous samples can
be obtained in the immediate vicinity of the engrafted tissue,
allowing for the analysis of islet-related metabolites and proteins.
In particular, this strategy has been used with the aim to define
early predictive markers of type 1 diabetes by detecting changes in
the metabolic profile (50), and to predict the risk of allograft
rejection to allow for a timely therapeutic intervention (51, 52). As
a whole, these methodologies using the ACE platform are perfectly
suited for the study of islet plasticity in health and disease under in
vivo conditions.LONGITUDINAL IMAGING OF
PANCREATIC ISLET CELL PLASTICITY:
VALIDATION STUDIES AND SCIENTIFIC
ADVANCES
Under various physiological circumstances islets can display a
certain degree of adaptation, for instance an increased demand
for insulin can lead to an increase in beta cell mass (68). The
modulation of beta cell function, either in some individual beta
cells within islets or in the entire population of beta cells, can also
serve as an adaptive biological mechanism of importance for the
maintenance of normoglycemia. Both physiological and
pathological states may cause changes in these adaptiveTABLE 1 | Morphological and functional parameters acquired in various studies
from islets transplanted into the ACE.
Parameters indicative of islet function and morphology References
Beta cell mass (36, 39–41)
Intra-islet vascular density and morphology (32, 42)
Blood flow dynamics (43)
Innervation (34)
Biochemical composition (44)
Beta cell-specific protein expression and localization (45)
Beta cell [Ca2+]i mobilization (33, 41, 46, 47)
NAD(P)H response (40, 48)
Insulin secretion status (39)
Beta cell insulin resistance (49)
Proteomic/metabolomic profile of islet microenvironment (50–52)
Autoimmune-induced damage (53–57)
Allorejection (51, 52, 58)
Cell death (38, 55, 59)April 2021 | Volume 12 | Article 652853
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normoglycemia and to the development of diabetes. One of the
major assets of the ACE as a transplantation/imaging platform is
to allow for the investigation of islet plasticity over a period of
several months, and thereby for the study of the diverse adaptive
procedures and circulating factors involved in the regulation of
beta cell mass and function.
Increase and Decrease in Beta Cell Mass
Longitudinal changes in beta cell mass have first been reported
for islets transplanted into the ACE of the ob/ob mouse model
(36). This mouse model lacks functional leptin and therefore its
uncontrolled appetite quickly leads to obesity. The study showed
that islets transplanted into the eye rapidly grow as a
consequence of beta cell hyperplasia, similarly to what has
been previously been reported for islets in their pancreas (69).
Islet volume doubled in a period of one month as a consequence
of beta cell proliferation, a result corroborating with the
impressive beta cell mass expansion seen in the pancreas by
OPT (70). Although the islets transplanted into the ACE cannot
fully represent the entire range of islets that are existing in the
pancreas, due to the different size distribution among isolated
islets as compared to in situ pancreatic islets (33, 59), we could
show that reporter islets in the ACE served as a representative
sample that displayed identical beta cell replication as compared
to in situ pancreatic islets. Also, the dilation of intra-islet blood
capillaries, suggested to be due to increased parasympathetic
innervation and endothelial nitric oxide production in ob/ob
mouse islets (71), was observed in the reporter islets.
Interestingly, both islet growth and enlarged capillaries were
shown to be dependent on the recipient mouse and not on the
origin of the transplanted islets, illustrating the importance of
circulating factors for these morphological phenotypes. In
addition, reporter islets in the ACE could be used to visualize
the efficiency of a treatment. For example, by daily
intraperitoneal injections of leptin, the appetite of ob/ob mice
was reduced and the growth of their islets was halted, both in the
ACE and in situ in the pancreas (36). Reporter islets were
similarly used in other studies for investigating changes in beta
cell mass when mice were fed a high fat diet (HFD) (40, 41).
Interestingly, islet growth was relatively modest under HFD-
induced prediabetes conditions (islet volumes were doubled after
a period of 4 month on HFD), and it was shown that the major
compensatory mechanism to cope with insulin resistance was a
change in islet function to increase insulin secretion from
individual beta cells (41).
A decrease in beta cell mass has also been documented with
islets transplanted into the ACE using various mouse models for
the study of diabetes. For instance, autoimmune destruction of
beta cells was assessed in the NOD mouse model, showing both
the infiltration of fluorescently-labelled immune cells and the
progressive and rapid destruction of islet cells following diabetes
onset (55). Interestingly, this study showed that during the short
pre-diabetes period, islet volumes were temporarily increased
and their scattering properties were five-fold reduced, indicative
of insulin hyper-secretion (39). These findings show thatFrontiers in Endocrinology | www.frontiersin.org 5reporter islets in the ACE allow for the early detection of the
pathogenesis of type 1 diabetes, with the potential to provide a
therapeutic intervention on a timely manner, before the full
development of diabetes. Beta cell ablation was also monitored in
other widely used mouse models for the study of diabetes and
hyperglycemia. The kinetics and extent of toxin-mediated beta
cell destruction were monitored both in the RIP-DTR (38) and in
the STZ-diabetic models (59), and validated by OPT image
analysis of islets in the pancreas. The destruction of islets in
the RIP-DTR mouse model was almost total after only a few
days, due to an immediate effect of the toxin fully occurring
during the day of administration and leading to the inhibition of
beta cell protein synthesis (72), and subsequently to beta cell
death. Interestingly, glucose handling started to be affected only 2
days after toxin administration despite a discontinuation in the
expression of all proteins required for glucose sensing/
metabolism and insulin granule secretion. This fact highlights
the over-capacity in terms of pancreatic islet function, displaying
a surprising functional reserve for the maintenance of blood
glucose levels. In mice rendered hyperglycemic by STZ, beta cell
mass was much less affected as compared to the RIP-DTR mouse
model. Beta cell ablation occurred mainly during the first week
after STZ administration, and mice became hyperglycemic with
more than half of their beta cell mass remaining (59). This study
demonstrated that STZ was mainly affecting the function of
pancreatic beta cells rather than beta cell mass. Interestingly,
when proceeding with a metabolic transplantation of islets into
the ACE following STZ-induced hyperglycemia, supporting the
remaining beta cells in the islets within the pancreas in their
efforts to regulate blood glucose homeostasis and thereby
reducing their metabolic stress, they partially recovered in
terms of function and maturity. Jointly, the results from this
study indicate that hyperglycemia in itself sustains a negative
feedback loop restraining the recovery of islet function, and
highlight the impressive plasticity of the endocrine pancreas,
even after STZ-induced damage (59).
Functional Plasticity of Pancreatic Islets
Although plasticity in beta cell function can be indirectly inferred
by the acquisition of physiological parameters, different
imageable indicators can be used to more specifically report on
beta cell function using islets engrafted into the ACE. For
instance in mice fed a HFD, beta cell [Ca2+]i dynamics were
monitored during the development of prediabetes by the use of
the GCaMP3 fluorescent indicator (41). In this study it was
shown that glucose-induced increase in beta cell [Ca2+]i was
already reduced after one week of HFD, and basal non-
stimulated levels of [Ca2+]i were increased progressively to a
significant level two months after introduction of the diet.
Combined with longitudinal imaging of beta cell mass, these
results demonstrate that alterations in beta cell function and
efficacy in terms of glucose-induced insulin release prevail over
the increase in beta cell mass to compensate for insulin resistance
in HFD-induced prediabetes (41). This study further showed
that, after 4 months of HFD, beta cell [Ca2+]i responses to
glucose could be reverted by refeeding mice a normal diet for 2April 2021 | Volume 12 | Article 652853
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Altogether these findings support the notion that beta cell
function should be the primary target for the treatment of
diet-induced diabetes rather than beta cell mass.
Glucose-induced [Ca2+]i responses were later investigated at the
single beta cell level in islets transplanted into the ACE of ob/ob
mice (46). While intravenously injected glucose was shown to reach
all beta cells simultaneously, both in control and ob/ob mice, this
resulted in the activation of only about 20% beta cells in the
hyperglycemic ob/ob mouse as compared to about 80% in control
mice, at 2 months of age. In another study using islets transplanted
into the ACE, it was shown that the number of responding beta cells
depends on their connectivity within the islet, which under normal
conditions increases when glucose levels are elevated (47). This
implies that beta cells are less coordinated in ob/ob as compared to
control mice. Interestingly, the percentage of responding beta cells
increased over time and became identical to control mice when they
reached 10 months of age (46). These findings illustrate the
functional plasticity occurring in islets of the ob/ob mouse over
time, and how reporter islets in the ACE allow for the investigation
of beta cell functional heterogeneity at single islet level.
Although beta cell connectivity was increased in the 10-
month-old ob/ob mice, not all aspects of their islet function
were improved. Indeed, it was shown using vibrational
microscopy and multivariate analysis, that reporter islets
transplanted into the ACE of ob/ob mice had a higher content
of collagen (44). This technique allows to register changes in the
chemical composition of tissues and in this case reported on an
increase in blood vessel fibrosis in ob/ob mouse islets. Electron
microscopy studies confirmed the strong deposit of collagen
fibers surrounding intra-islet endothelial cells, both in islets in
the pancreas and in islets engrafted into the ACE. Fibrosis of islet
blood vessels has been similarly detected in old mice by ex vivo
analysis of islets transplanted into the ACE (31), altogether
pointing to a natural, progressive and irreversible increase of
fibrosis over time that is exacerbated by diabetic conditions.DISCUSSION
Over the years, in vivo imaging of islets transplanted into the ACE
has proven to be a remarkably valuable tool for the study of
pancreatic islet biology and plasticity. Despite the numerous
scientific findings obtained from its use, a few limitations have
however to be acknowledged. First and foremost, islets engrafted
into the ACE might not reflect in all respects the function and
plasticity of islets in situ in the pancreas, simply due to their different
location. For instance, even though engrafted islets are properly
innervated both by sympathetic and parasympathetic neurons, they
likely are not connected by circuits emanating from the
hypothalamic regions as is the case for in situ pancreatic islets
(73). The potentiating effect of light on insulin secretion from islets
engrafted into the ACE (34) is indicative of connections from the
grafts to the visual cortex instead, as demonstrated for other tissues
engrafted into the ACE (18). Also, the relative location of theFrontiers in Endocrinology | www.frontiersin.org 6engrafted islets with regard to other organs contributing to blood
glucose homeostasis is different from that of islets in the pancreas,
which may have functional implications. For example, while the
liver is the first organ exposed to insulin released from islets in the
pancreas and is the main contributor to insulin clearance (74–77),
insulin released from engrafted islets will first encounter other
organs before reaching the liver at a progressively diminished
concentration. Although it would imply that islets transplanted
into the ACE might not utterly mirror in situ pancreatic islets in
their functionality, this very fact can potentially shed light on the
importance of a stepwise presentation of insulin at different
concentrations to different organs for the normal function of the
endocrine pancreas. In this respect, it is interesting to note that only
about 100 islets are required to be transplanted into the ACE of a
mouse devoid of functional in situ pancreatic islets (37, 59, 66),
which suggests a seemingly more efficient insulin signaling between
engrafted islets and peripheral organs. Finally, potential endocrine-
exocrine interactions in the pancreas, of beneficial or detrimental
nature for islet function, will not apply to islets transplanted into the
ACE. It is therefore of importance to keep these differences in mind
when studying islets engrafted into the ACE, and possibly even
make use of these to reveal specific aspects related to the function of
in situ pancreatic islets and to inter-organ communication in health
and disease.
Contrasting to the use of the ACE to study transplanted islets
as “reporters”, mirroring as accurately as possible pancreatic islet
function and plasticity, the ACE can also be a valuable
transplantation site to investigate in detail the role of specific
genes and signaling pathways on islet function. For instance, islet-
expressed ApoCIII was shown by longitudinal in vivo imaging and
ex vivo functional assessment to have a major role in islet growth
and signaling (48). Also, transplantation of islets from different
species (mouse, human, monkey) into the ACE of mice revealed
that intra-islet paracrine interactions are major determinants of
the resting glycemic set point in vivo (66). The accumulation of
such discoveries can serve as the basis for the establishment of all
fundamental parameters required for proper islet function.
Moreover, and in addition to establishing this optimal
repertoire, a further possible “enhancement” of islet function
could prove to be beneficial for future clinical transplantation,
which suffer to this day from poor islet quality and survival (78).
This transplantation and imaging platform has indeed already
been successfully used to assess functional enhancement of
synthetically engineered islet-derived pseudoislets (33). It could
similarly be used in the relatively near future to study potentially
beneficial effects of modifying GPCR signaling pathways and/or
intra-islet paracrine interactions (79), incorporating supporting
structures or accessory cells in islets (80), or using stem cells as a
new source of mature islet cells (81–83), altogether supporting the
development of promising strategies to improve the outcome of
clinical transplantations. In conclusion, the ACE has been a
remarkable research platform that is being adopted by an
increasing number of scientists for the study of islet function
and survival, and without doubt will continue to support novel
findings in the field of islet biology and innovative therapeutic
approaches for diabetes treatment.April 2021 | Volume 12 | Article 652853
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